Letter to the editor: Is PAI-1 a thrombotic biomarker in NASH cirrhosis?
- PMID: 35112379
- DOI: 10.1002/hep.32392
Letter to the editor: Is PAI-1 a thrombotic biomarker in NASH cirrhosis?
Comment on
-
NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH.Hepatology. 2022 Jul;76(1):172-185. doi: 10.1002/hep.32274. Epub 2022 Jan 22. Hepatology. 2022. PMID: 34890063 Free PMC article. Clinical Trial.
References
REFERENCES
-
- Stine JG, Schreibman IR, Faust AJ, Dahmus J, Stern B, Soriano C, et al. NASHFit: a randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH. Hepatology. 2022;76:172-85.
-
- Rossetto V, Spiezia L, Senzolo M, Rodriguez-Castro KI, Gavasso S, Woodhams B, et al. Does decreased fibrinolysis have a role to play in the development of non-neoplastic portal vein thrombosis in patients with hepatic cirrhosis? Intern Emerg Med. 2014;9:397-403.
-
- Zanetto A, Campello E, Bulato C, Gavasso S, Saggiorato G, Shalaby S, et al. More pronounced hypercoagulable state and hypofibrinolysis in patients with cirrhosis with versus without HCC. Hepatol Commun. 2021;5:1987-2000.
-
- Zanetto A, Rinder HM, Campello E, Saggiorato G, Deng Y, Ciarleglio M, et al. Acute kidney injury in decompensated cirrhosis is associated with both hypo-coagulable and hyper-coagulable features. Hepatology. 2020;72:1327-40.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
